Nevro Corp (NYSE:NVRO) Expected to Announce Earnings of -$0.83 Per Share

Wall Street brokerages expect Nevro Corp (NYSE:NVRO) to report earnings of ($0.85) per share for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Nevro’s earnings, with the lowest EPS estimate coming in at ($0.96) and the highest estimate coming in at ($0.68). Nevro posted earnings of ($0.32) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 165.6%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, November 6th.

On average, analysts expect that Nevro will report full-year earnings of ($3.99) per share for the current financial year, with EPS estimates ranging from ($4.26) to ($3.36). For the next financial year, analysts forecast that the company will report earnings of ($3.08) per share, with EPS estimates ranging from ($3.81) to ($1.35). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Nevro.

Nevro (NYSE:NVRO) last announced its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported ($0.58) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.85) by $0.27. Nevro had a negative net margin of 24.51% and a negative return on equity of 41.07%. The business had revenue of $100.16 million for the quarter, compared to analyst estimates of $92.27 million. During the same period in the prior year, the business posted ($0.37) earnings per share. Nevro’s revenue was up 4.7% compared to the same quarter last year.

Several equities analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Nevro from a “sell” rating to a “hold” rating and set a $67.00 price objective on the stock in a report on Tuesday, August 13th. Morgan Stanley set a $76.00 price objective on shares of Nevro and gave the company a “buy” rating in a report on Friday, August 9th. Northland Securities set a $65.00 price objective on shares of Nevro and gave the company a “hold” rating in a report on Friday, August 9th. Leerink Swann set a $98.00 price objective on shares of Nevro and gave the company a “buy” rating in a report on Friday, August 23rd. Finally, ValuEngine lowered shares of Nevro from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $76.10.

Shares of NYSE NVRO opened at $85.25 on Thursday. The company’s 50 day simple moving average is $84.80 and its 200 day simple moving average is $72.19. Nevro has a fifty-two week low of $34.75 and a fifty-two week high of $91.60. The firm has a market capitalization of $2.71 billion, a P/E ratio of -51.98 and a beta of 0.21. The company has a debt-to-equity ratio of 0.89, a current ratio of 6.05 and a quick ratio of 4.66.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD raised its holdings in Nevro by 91.5% in the second quarter. Price T Rowe Associates Inc. MD now owns 3,078,635 shares of the medical equipment provider’s stock worth $199,588,000 after purchasing an additional 1,470,807 shares during the period. Vanguard Group Inc. raised its holdings in Nevro by 4.0% in the second quarter. Vanguard Group Inc. now owns 2,670,677 shares of the medical equipment provider’s stock worth $173,140,000 after purchasing an additional 102,183 shares during the period. BlackRock Inc. raised its holdings in Nevro by 1.2% in the second quarter. BlackRock Inc. now owns 2,583,530 shares of the medical equipment provider’s stock worth $167,491,000 after purchasing an additional 29,637 shares during the period. D. E. Shaw & Co. Inc. raised its holdings in Nevro by 11.7% in the second quarter. D. E. Shaw & Co. Inc. now owns 2,067,400 shares of the medical equipment provider’s stock worth $134,029,000 after purchasing an additional 216,680 shares during the period. Finally, Invesco Ltd. raised its holdings in Nevro by 316.2% in the second quarter. Invesco Ltd. now owns 1,970,969 shares of the medical equipment provider’s stock worth $127,778,000 after purchasing an additional 1,497,455 shares during the period.

About Nevro

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Recommended Story: Initial Coin Offerings entail a high degree of risk

Get a free copy of the Zacks research report on Nevro (NVRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.